联生药（扬州)的生物制药研发与生产基地,占地 1.3 万平米,提供一站式 CDMO 服务,从原液到药品的无菌灌装 cGMP 生产。生产规模涵盖 50L/200L/500L/2000L,  支持前临床和临床的 IND 报批,以及后期 BLA 审批和早期的商业化生产。我们 团队拥有超过 10 年的单抗和重组蛋白生产经验, 实现了 6+个创新药物在中国和 美国的临床报批。持续地精进与强化生物工艺,在质量源于设计和质量风险管理 的原则下,确保产品整个生命周期的质量并且符合经济效益。透过建立灵活的伙 伴关系,以及一体化的服务平台: 高效敬业的项目团队, 国际标准的质量管理, 优 质的 CMC 文件, 全方位支持客户完成个阶段的研发和报批任务。

The R&D and production base of United Biopharma(Yangzhou) covers an area of  13,000 square meters and provides one-stop CDMO services for cGMP production of  drug substance and drug product by aseptic filling, which production scale includes  50L/200L/500L/2000L, supporting pre-clinical and clinical IND approval, as well as  the later BLA approval and early commercial production. Our team has more than 10  years of experience in the production of mAb and recombinant proteins, and has  achieved clinical approval of 6+ innovative biologics in China and the United States.  Continue to improve and intensify the bioprocess, meanwhile ensure the product quality  during R&D life cycle, balanced with the economic benefits under implementing quality-by-design and quality risk management. Through the establishment of flexible  partnerships, and an integrated service platform: efficient and dedicated project team,  international standard quality management, high-quality CMC documents, all-round  support for our clients to accomplish each R&D stage and IND approval tasks.